BridgeBio Pharma Shares Positive Results of Single-Arm Phase

BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months

- Phase 3 open-label, single-arm study conducted in Japan by BridgeBio licensing partner Alexion, AstraZeneca Rare Disease showed consistency with global ATTRibute-CM Phase III trial - No mortality...

Related Keywords

Japan , Ukraine , Vikram Bali , Twitter , Bio Pharma Inc , Securities Exchange , Exchange Commission , Bridgebio Pharma Inc , Nasdaq , Eidos Therapeutics Inc , Linkedin , Astrazeneca Rare Disease , Win Ratio , Bio Pharma , Japan Phase , Astrazeneca Rare , Eidos Therapeutics , Bridgebio Pharma , Securities Act , Securities Exchange Act , Exchange Act , Middle East , Risk Factors , Annual Report , Bio Media Contact , Markets ,